2,070.00
+17(+0.83%)
Currency In JPY
Address
10-11 Nihonbashi Kobuna-cho
Tokyo, 103-8351
Japan
Phone
81 3 3663 2351
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1777
First IPO Date
January 01, 2001
Name | Title | Pay | Year Born |
Mr. Sachiaki Ibe | Chairman & Chief Executive Officer | 0 | 1941 |
Ms. Yuuki Okazawa | Managing Executive Officer & Director | 0 | 1965 |
Mitsuru Iwai | Executive Officer & GM of Production & Logistics Headquarters | 0 | N/A |
Kazuhiro Akiba | Executive Officer & GM of Pharmaceutical Sales Division | 0 | N/A |
Yasuhisa Tanaka | Executive Officer and GM of Finance & Accounting Division | 0 | N/A |
Mr. Hiroki Kato | Managing Executive Officer and GM of Asian Business, Planning Department & Business Development | 0 | 1963 |
Mr. Yoshihiro Hiraga | Executive Officer and GM of Research & Development Headquarters, Licensing Office | 0 | 1957 |
Mr. Mitsuhiro Ibe | President, Chief Operating Officer & Representative Director | 0 | 1971 |
Toshiaki Kawagoe | Executive Officer and GM of Reliability Assurance Headquarters & Customer Relations Office | 0 | 1961 |
Kenji Kusano | Executive Officer & GM of Consumer Healthcare Sales Division | 0 | 1963 |
Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; sclerosing agent for varicose veins; anti-inflammatory topical blood circulation enhancers; non-steroidal anti-inflammatory ophthalmic solutions; absorbable topical hemostat products; and proton pump inhibitors. In addition, it offers consumer healthcare products, such as nutritional health drugs, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, and food for specified health uses. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.